Pharmaceutical

LY-3541860 by Eli Lilly and Co for Relapsing Multiple Sclerosis (RMS): Likelihood of Approval

LY-3541860 is under clinical development by Eli Lilly and Co and currently in Phase II for Relapsing Multiple Sclerosis (RMS).

May 17, 2024 - 04:00
LY-3541860 is under clinical development by Eli Lilly and Co and currently in Phase II for Relapsing Multiple Sclerosis (RMS).
Read the original article

Tags:

Previous Article

MRNA-1365 by Moderna for Human Metapneumovirus Infections: Likelihood of Approval

Next Article

LZ-901 by Beijing Luzhu Biotechnology for Herpes Zoster (Shingles): Likelihood o...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Latest data shows millions of eligible Americans have been disenrolled from Medicaid

Latest data shows millions of eligible Americans have b...

Nov 3, 2023

WHO recommends dropping component of many flu vaccines

WHO recommends dropping component of many flu vaccines

Sep 30, 2023

STAT+: Humana slashes profit predictions amid soaring Medicare Advantage costs

STAT+: Humana slashes profit predictions amid soaring M...

Jan 18, 2024